Search research articles
Contact Us
Filters
Showing results (71-80 of 128) with videos related to
Page
of 13
Sort By:
International Journal of Laboratory Hematology
|
April 7, 2019
The potential value of thrombin generation assay in the diagnosis of FV inhibitors
Stéphanie Désage, Emilie Jousselme, Sandra Le Quellec, et al.
Plos One
|
November 18, 2017
Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?
Yohann Jourdy, Nathalie Enjolras, Sandra Le Quellec, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 18, 2023
Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey
Valérie Chamouard, Julie Freyssenge, Gaetan Duport, et al.
British Journal of Haematology
|
October 31, 2015
Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation
Yesim Dargaud, Yohann Jourdy, Sandra Le Quellec, et al.
Seminars in Thrombosis and Hemostasis
|
June 16, 2026
Comparison of the coagulation profile following treatment of major surgical haemorrhage with fresh frozen plasma or fibrinogen concentrate
Ian James Bruce Young, Neill Aitken, Anna Dickson, et al.
Leukemia & Lymphoma
|
April 4, 2019
The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?
Yesim Dargaud, Marc Fouassier, Jean Claude Bordet, et al.
Acta Haematologica
|
September 28, 2020
Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia
Karim Abdelmoumen, Marc Fabre, Sophie Ducastelle-Lepretre, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 8, 2025
Utilising Thrombin Generation Assay to Guide Co-Administration of Factor Therapies With Fitusiran
Yesim Dargaud, Christophe Nougier, Stephanie Desage, et al.
Thrombosis and Haemostasis
|
May 12, 2026
Thrombin Generation as a Potential Surrogate Marker of Hemostatic Status in the Era of Novel Therapies for Hemophilia
Yesim Dargaud, Giancarlo Castaman, Roberta Gualtierotti, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
May 22, 2026
In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab
Maissaa Janbain, Laurie Josset, Alexandre Leuci, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 128) with videos related to
Sort By:
Page
of 13
International Journal of Laboratory Hematology
|
April 7, 2019
The potential value of thrombin generation assay in the diagnosis of FV inhibitors
Stéphanie Désage, Emilie Jousselme, Sandra Le Quellec, et al.
Plos One
|
November 18, 2017
Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?
Yohann Jourdy, Nathalie Enjolras, Sandra Le Quellec, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 18, 2023
Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey
Valérie Chamouard, Julie Freyssenge, Gaetan Duport, et al.
British Journal of Haematology
|
October 31, 2015
Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation
Yesim Dargaud, Yohann Jourdy, Sandra Le Quellec, et al.
Seminars in Thrombosis and Hemostasis
|
June 16, 2026
Comparison of the coagulation profile following treatment of major surgical haemorrhage with fresh frozen plasma or fibrinogen concentrate
Ian James Bruce Young, Neill Aitken, Anna Dickson, et al.
Leukemia & Lymphoma
|
April 4, 2019
The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?
Yesim Dargaud, Marc Fouassier, Jean Claude Bordet, et al.
Acta Haematologica
|
September 28, 2020
Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia
Karim Abdelmoumen, Marc Fabre, Sophie Ducastelle-Lepretre, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 8, 2025
Utilising Thrombin Generation Assay to Guide Co-Administration of Factor Therapies With Fitusiran
Yesim Dargaud, Christophe Nougier, Stephanie Desage, et al.
Thrombosis and Haemostasis
|
May 12, 2026
Thrombin Generation as a Potential Surrogate Marker of Hemostatic Status in the Era of Novel Therapies for Hemophilia
Yesim Dargaud, Giancarlo Castaman, Roberta Gualtierotti, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
May 22, 2026
In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab
Maissaa Janbain, Laurie Josset, Alexandre Leuci, et al.
Page
of 13